To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

This document is hosted on the original agency website.

Some city and county websites restrict direct document access. If the document does not open, it may need to be viewed from that agency's own website.

Document Information